ABSTRACT
OBJECTIVE：To study the abnormal use of anti-tumor dr ugs i n the clinic in order to provide reference for rational use of drugs in the clinic. METHODS ：Referring to foreign and domestic anti-tumor drug use guidelines and literatures ，Guidelines for Clinical Use of New Anti-tumor Drugs （2018 edition），Off-label Drug Use List （2019 edition），Practical Oncology （secondary edition），anti-tumor drug package inserts approved by FDA and package inserts of anti-tumor drug listed in China ，abnormal use of antitumor drugs （including instructions ，special indications ，and the order of administration of new anti-tumor drugs ） was summarized and analyzed. RESULTS & CONCLUSIONS ：The off-label use of anti-tumor drugs were summarized in this paper ， including 11 drug varieties and 4 kinds of off-label drug items ，such as off-label drug use plan （recombinant human endostatin ， rituximab），off-label administration route （pemetrexed disodium ，bortezomib，bevacizumab），off-label administration lines （erlotinib，gefitinib），off-label drug dosage （actinomycin D ，gemcitabine，ifosfamide，etoposide）. They should be carefully selected and strictly monitored in clinical use ，and treatment plan should be adjusted according to needs. Among the special indications，cyclophosphamide，cytarabine，methotrexate and cisplatin were used in large doses ，which were 2 000-2 400 mg/m2， 2 000 mg/m2，12 g/m2 and 80-120 mg/m2，respectively；individual differences should be paid attention to and therapeutic drug monitoring should be carried out if necessary. In the scheme of combination of new anti-tumor drugs or traditional chemotherapy drugs，there were 5 categories and 11 items in total ，such as combination of molecular targeted anti-tumor drugs with traditional chemotherapy drugs （such as docetaxel at first ，gefitinib at the same time or later ），combination of target immunocheckpoint drugs with traditional chemotherapy drugs （such as platinum at first ，then nivolumab ），and molecular targeted anti-tumor drugs combination（such as pertuzumab and trastuzumab should be given in sequence ，in either order ）. In clinical use ，histopathological diagnosis should be made clear ， and drugs with specific targets should be used after gene detection and strictly follow the indications.
ABSTRACT
Objective:To explore correlation among heart structure , cardiac function and premature ventricular systo‐le (PVS) of different loads ,.Methods :A total of 220 PVS patients treated in our hospital were selected .According to PVS number‐to‐24h total heart rate ratio ,they were divided into low load group (20% ,n=62) .Another 68 subjects without PVS were regarded as normal control group .Cardiac function indexes and serum level of N terminal pro brain natriuretic peptide (NT‐proBNP) were measured in all groups ,and their correlation was analyzed .Results :Compared with normal control group ,there were significant rise in QT interval ,QRS wave duration and corrected QT interval in medium and high load groups , P<0.05 or <0.01. Compared with normal control group ,there were significant rise in left atrial di‐ameter ( LAD ) , left ventricularoutflow tract dimension ( LVOT ) , left ventricular end‐diastolic dimension (LVEDd) ,right ventricular end‐diastolic dimension (RVEDd) ,left ventricular end‐diastolic volume (LVEDV) , stroke volume (SV) ,left ventricular mass index (LVMI) and NT‐proBNP level ,and significant reduction in left ventricular ejection fraction (LVEF) in medium and high load group ,P<0.05 or <0.01. Bivariate linear correla‐tion analysis indicated that PVS load was significant linear positively correlated with QRS wave duration ,corrected QT interval ,LVEDd ,RVEDd and NT‐proBNP level (r=0.42~0.65 ,P<0.01 all);and significant linear inverse‐ly correlated with LVEF (r= -0.62 ,P=0.001) .Conclusion:Changes may occur in left ventricular structure and function along with PVS load rises .Therefore ,attention should be paid on monitoring related indexes in order to perform early intervention .
ABSTRACT
Background and purpose:Quinonoids can change the cell cycle distribution of tumor cells, and effect the radiosensitizing. This study aimed to investigate the radiosensitization effects, cell cycle and apoptosis of cryptotanshinone on H22 hepatoma-bearing mice. Methods:The mouse hepatoma H22 model was established, then divided into blank control group, irradiation alone group, high dose of cryptotanshinone group, cryptotanshinone (low, medium and high)+IR groups. After irradiated, observed the growth of tumor’s conditions, record epigenetic tumor irradiation time, calculated the delay time of tumor growth and enhancement factor (EF). After 22 days, mice were killed, stripped tumor, and calculated the inhibition rate. The cell cycle distribution and apoptosis were measured by lfow cytometry. Results:Cryptotanshinone (low, medium and high) groups inhibited the tumor growth better than the blank group, and had the signiifcant radiosensitizing effect. The enhancement factor was 1.22, 1.43,2.19, respectively. Cells were treated with cryptotanshinone which had significant effects on cell cycle, and induced apoptosis, which indicated signiifcant G2/M phase arrest and a decrease in S phase. Conclusion:Cryptotanshinone inhibited the tumor growth and had the radiosensitizing effects on H22 hepatoma-bearing mice. One of the mechanism may be that it might make significant G2/M phase arrest and S phase decreased, and induced apoptosis. So cells were more sensitive to radiation.